$VTEX

Gomes Andre Spolidoro Ferreira sold $11K of VTEX

Gomes Andre Spolidoro Ferreira (Chief Strategy Officer) sold 3,000 shares of VTEX (VTEX) at $3.60 on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gomes Andre Spolidoro Ferreira
Published Jun 17, 2026, 7:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 7:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VTEX
Neutral
high confidence
Mentioned
$VTEX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VTEXNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (3,000 shares at $3.60) by the Chief Strategy Officer under a Rule 10b5-1 plan; this is typically informational rather than a fundamental catalyst.

02

Market read

Traders may treat this as low-signal insider activity; it can slightly influence sentiment but is unlikely to drive price without additional catalysts.

03

What to watch

The disclosed sale size is relatively small and the plan is pre-arranged, so the market may discount it; any signal would be more credible if paired with other insider buys/sales or operational news.

Relevance 2/10Novelty 6/10Timing: Filed 2026-06-17; transaction dated 2026-06-16

Background

The article is an SEC Form 4 insider transaction disclosure for VTEX, reported via EDGAR.

Company-level read

Ticker impact

$VTEXNeutralHigh confidence
Context

VTEX disclosed an officer (Chief Strategy Officer) open-market sale of 3,000 shares at $3.60 on a Rule 10b5-1 plan.

Expected impact

Near-term impact likely muted; any reaction would be small unless accompanied by unusual volume or broader news.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan and modest disclosed value (~$10.8k), which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution; traders may watch for follow-on sales or changes in selling cadence.

Key entities

  • VTEX

    Issuer of the Form 4 insider transaction; officer sale disclosed.

  • Gomes Andre Spolidoro Ferreira

    Chief Strategy Officer who sold 3,000 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VTEXMed

VTEX (VTEX) Just Turned A Profit Corner, But Growth Is Slowing

VTEX (NYSE:VTEX) reported Q2 2026 results showing improved profitability with non-GAAP income from operations up 62.4% YoY to $13.8M, and free cash flow up 79.1% to $12.7M. However, revenue growth slowed to 1.3% YoY on an FX-neutral basis, with management expecting flat growth for Q3. The company repurchased 6.2M shares for $23.2M during the quarter.

$VTEXMedAI 8/10

VTEX (VTEX) Q2 2026 Earnings Call Transcript

VTEX reported Q2 2026 results in an earnings call. GMV was $5.7B, up 7% FX-neutral. Subscription revenue was $63.8M, up 1.3% FX-neutral. Non-GAAP operating income rose 62% to $13.8M, with a 21.4% margin. Free cash flow was $12.7M, up 79%. Q3 guidance calls for flat FX-neutral subscription growth.

$VTEXMedAI 8/10

VTEX Q2 Earnings Call Highlights

VTEX (NYSE:VTEX) reported Q2 margin and cash flow improvement and guided for Q3 and full-year low-single-digit FX-neutral subscription revenue growth and low-20% non-GAAP operating and free cash flow margins. Q2 non-GAAP subscription gross margin rose to 81.8%. Free cash flow rose 79% to $12.7M. VTEX repurchased 6.2M shares at $3.76.

$VTEXMed

VTEX (VTEX): Financial results for Q2 2026

VTEX (VTEX) furnished an SEC Form 6-K — earnings release. VTEX Reports Second Quarter 2026 Financial Results Subscription revenue grew 11.4% (+1.3% FXN), with GMV up 17.8% (+7.0% FXN) Non-GAAP income from operations increased 62.4% to US$13.8 million, reaching a 21.4% margin Free cash flow increased 79.1% to US$12.7 million, reaching a